The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer

Miyoshi, Ai; Isohashi, Fumiaki; Fujii, Makoto; Iwamiya, Tadashi; Takemura, Masahiko; Nagase, Yoshikazu; Yokoi, Takeshi; Yoshioka, Emi; Ito, Kimihiko; Yamabe, Eri; Masuhara, Kanji; Tsujie, Tomoko; Kimura, Tadashi; Kodama, Michiko

doi:https://doi.org/10.1002/ijgo.70077

The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer

Miyoshi, Ai; Isohashi, Fumiaki; Fujii, Makoto et al.

International Journal of Gynecology and Obstetrics, 2025

アクセス数:12件（2025-05-03 14:07 集計）

固定URL: https://hdl.handle.net/11094/100968

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
IntJGynecolObstet	pdf	なし	831 KB	8	2025.04.15

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer
著者	著者名 Miyoshi, Ai
	NRID 1000000448036 1000000448036 著者名 Isohashi, Fumiaki
	NRID 1000010803760 1000010803760 ORCID 0000-0003-4436-7456 0000-0003-4436-7456 researchmap permalink m-fujii m-fujii Scopus Author ID 55738467300 55738467300 著者名 Fujii, Makoto
	NRID 1000040790936 1000040790936 著者名 Iwamiya, Tadashi
	NRID 1000050294062 1000050294062 著者名 Takemura, Masahiko
	著者名 Nagase, Yoshikazu
	著者名 Yokoi, Takeshi
	著者名 Yoshioka, Emi
	著者名 Ito, Kimihiko
	著者名 Yamabe, Eri
	著者名 Masuhara, Kanji
	NRID 1000050362695 1000050362695 著者名 Tsujie, Tomoko
	NRID 1000090240845 1000090240845 著者名 Kimura, Tadashi
	NRID 1000070791391 1000070791391 ORCID 0000-0003-4046-7572 0000-0003-4046-7572 researchmap permalink mkyh mkyh Scopus Author ID 35422516200 35422516200 著者名 Kodama, Michiko
キーワード等	advanced cancer
	cervical cancer
	chemotherapy
	metastasis
	prognosis
	radiotherapy
内容	Miyoshi A., Isohashi F., Fujii M., et al. The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer. International Journal of Gynecology and Obstetrics , (2025); https://doi.org/10.1002/ijgo.70077.
抄録	Objective: Systemic platinum-based chemotherapy is the first-line treatment of choice for metastatic cervical cancer. While subsequent radiotherapy after primary chemotherapy is a potential option, its benefit remains unclear. This multicenter retrospective study aimed to evaluate whether post-chemotherapy radiotherapy improves the prognosis of metastatic cervical cancer. Methods: We retrospectively analyzed 46 eligible patients, including 22 patients receiving chemotherapy-alone and 24 patients receiving chemotherapy followed by subsequent radiotherapy. Medical records were retrospectively reviewed for patient characteristics, subsequent treatment modality, adverse events during the treatment course, metastasis site, recurrence or progression, and recurrence sites. Fisher exact test or chi-squared test, the Mann–Whitney U test, log-rank test, and Cox proportional hazards model were used. Results: The 2-year overall survival (OS) rate for all patients was 47%, with the median OS of 24.8 months. Patients receiving chemotherapy alone (chemotherapy-alone group) had a 2-year OS rate of 23%, while those receiving subsequent radiotherapy (chemotherapy-radiotherapy group) had a significantly higher OS rate of 67% (HR = 2.83, P = 0.006). The 2-year progression-free survival (PFS) rates were 9% and 33%, respectively (HR = 3.25, P = 0.010). Serious adverse events occurred in 46.2% of the chemotherapy-alone group and 29.2% of the chemotherapy-radiotherapy group during subsequent treatment (P = 0.249). Conclusion: Post-chemotherapy radiotherapy may improve the prognosis of metastatic cervical cancer without increasing serious adverse events. Further prospective studies are warranted to validate these findings.
出版者	John Wiley and Sons Ltd
収録物名	International Journal of Gynecology and Obstetrics
刊行年月	2025-03-22
言語	英語
ハンドルURL	https://hdl.handle.net/11094/100968
PISSN	00207292
eISSN	18793479
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1002/ijgo.70077
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	International Journal of Gynecology and Obstetrics. 2025
DC.title	The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer
DC.creator	Miyoshi, Ai
	Isohashi, Fumiaki
	Fujii, Makoto
	Iwamiya, Tadashi
	Takemura, Masahiko
	Nagase, Yoshikazu
	Yokoi, Takeshi
	Yoshioka, Emi
	Ito, Kimihiko
	Yamabe, Eri
	Masuhara, Kanji
	Tsujie, Tomoko
	Kimura, Tadashi
	Kodama, Michiko
DC.publisher	John Wiley and Sons Ltd
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-03-22
DC.identifier	https://doi.org/10.1002/ijgo.70077
DC.subject	advanced cancer
	cervical cancer
	chemotherapy
	metastasis
	prognosis
	radiotherapy
DC.description	Miyoshi A., Isohashi F., Fujii M., et al. The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer. International Journal of Gynecology and Obstetrics , (2025); https://doi.org/10.1002/ijgo.70077.
DCTERMS.abstract	Objective: Systemic platinum-based chemotherapy is the first-line treatment of choice for metastatic cervical cancer. While subsequent radiotherapy after primary chemotherapy is a potential option, its benefit remains unclear. This multicenter retrospective study aimed to evaluate whether post-chemotherapy radiotherapy improves the prognosis of metastatic cervical cancer. Methods: We retrospectively analyzed 46 eligible patients, including 22 patients receiving chemotherapy-alone and 24 patients receiving chemotherapy followed by subsequent radiotherapy. Medical records were retrospectively reviewed for patient characteristics, subsequent treatment modality, adverse events during the treatment course, metastasis site, recurrence or progression, and recurrence sites. Fisher exact test or chi-squared test, the Mann–Whitney U test, log-rank test, and Cox proportional hazards model were used. Results: The 2-year overall survival (OS) rate for all patients was 47%, with the median OS of 24.8 months. Patients receiving chemotherapy alone (chemotherapy-alone group) had a 2-year OS rate of 23%, while those receiving subsequent radiotherapy (chemotherapy-radiotherapy group) had a significantly higher OS rate of 67% (HR = 2.83, P = 0.006). The 2-year progression-free survival (PFS) rates were 9% and 33%, respectively (HR = 3.25, P = 0.010). Serious adverse events occurred in 46.2% of the chemotherapy-alone group and 29.2% of the chemotherapy-radiotherapy group during subsequent treatment (P = 0.249). Conclusion: Post-chemotherapy radiotherapy may improve the prognosis of metastatic cervical cancer without increasing serious adverse events. Further prospective studies are warranted to validate these findings.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	100968
citation_title	The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer
citation_author	Miyoshi, Ai
	Isohashi, Fumiaki
	Fujii, Makoto
	Iwamiya, Tadashi
	Takemura, Masahiko
	Nagase, Yoshikazu
	Yokoi, Takeshi
	Yoshioka, Emi
	Ito, Kimihiko
	Yamabe, Eri
	Masuhara, Kanji
	Tsujie, Tomoko
	Kimura, Tadashi
	Kodama, Michiko
citation_publisher	John Wiley and Sons Ltd
citation_language	英語
citation_date	2025-03-22
citation_journal_title	International Journal of Gynecology and Obstetrics
citation_doi	https://doi.org/10.1002/ijgo.70077
citation_public_url	https://hdl.handle.net/11094/100968

The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer

閲覧可能ファイル

論文情報

論文詳細を表示